Another Award I Nominate Me For: PM360's Trailblazer Award
(Source: Pharma Marketing Blog)
Source: Pharma Marketing Blog - February 24, 2014 Category: Pharma Commentators Tags: Awards Trailblazer Award Source Type: blogs
Endo Health to Pay $192.7M in Settlement
Endo Health will pay almost $193 million to resolve claims that it improperly marketed the shingles treatment Lidoderm for unapproved uses like treating lower back pain.The Malvern, Pa., drugmaker will pay $171.9 million in civil false claims settlements largely to the federal government, with $34.2 million from that total going to 47 states and the District of Columbia. Endo also agreed to pay $20.8 million as part of a deferred prosecution agreement.Federal prosecutors said Friday that Endo Health Solutions Inc. marketed the drug for unapproved uses between 2002 and 2006.Endo said it was pleased to resolve the issue, and...
Source: PharmaGossip - February 24, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Kerching - another whistleblower wins
By Jonathan Stempel(Reuters) - CareFusion Corp agreed to pay $40.1 million to settle a federal government lawsuit accusing it of paying kickbacks to boost sales of a pre-surgical skin treatment, and marketing the product for unapproved uses.The accord announced on Thursday by the U.S. Department of Justice resolves allegations that CareFusion violated the federal False Claims Act by paying $11.6 million to a doctor to promote its ChloraPrep product to healthcare providers.That doctor, Charles Denham, received the kickbacks while serving as co-chair of the safe practices committee of the nonprofit National Quality Forum, wh...
Source: PharmaGossip - February 24, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Here’s Why Novartis’ Japanese Unit Was Raided
Last month, the Japanese Health Ministry filed a complaint against Switzerland-based drugmaker Novartis AG’s (NYSE:NVS) Japan unit after the company used allegedly false data to advertise for its best-selling blood pressure drug, Diovan, theWall Street Journal reports.Reuters reports that prosecutors in Tokyo broke into the company’s offices in Japan on Wednesday as part of a criminal investigation of the company following charges that the drugmaker violated the law by releasing misleading advertisements.The advertisements in question cited research which the Japanese Health...
Source: PharmaGossip - February 23, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
GlaxoChinaGate contd. - Enter the British Serious Fraud Office Dragon
This article appeared in the South China Morning Post print edition as UK fraud office probes firms over briberyhttp://www.scmp.com/business/companies/article/1432456/gsk-rolls-royce-may-be-british-serious-fraud-offices-hit-list (Source: PharmaGossip)
Source: PharmaGossip - February 21, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
